Director/PDMR Dealing

Released : 04/04/2017 17:47:00

RNS Number : 5908B
Creo Medical Group PLC
04 April 2017
 

Creo Medical Group plc

 

Director/PDMR Dealing

 

The Company has been informed that directors Craig Gulliford (Chief Executive Officer) and Chris Hancock (Chief Technology Officer) have today each transferred ordinary shares of 0.1p each ("Ordinary Shares") in the Company from their personal holdings to their self-invested personal pensions ("SIPP"), as follows.

 

Director

Number of Ordinary Shares sold from personal account

Price per Ordinary Share sold

Number of Ordinary Shares purchased into SIPP

Price paid per Ordinary Share by SIPP

Craig Gulliford

92,750

82.5p

92,704

82.5p

Chris Hancock

106,084

82.5p

106,038

82.5p

 

Following these transactions, Mr Gulliford and Mr Hancock's total interest in the Company are 1,089,886 Ordinary Shares and 4,880,150 Ordinary Shares respectively.

 

Template for notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

Craig Gulliford

 

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Chief Executive Officer

b)

 

Initial notification /Amendment

 

 

Initial

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

Creo Medical Group plc

b)

 

LEI

 

 

N/A

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

 

 

Ordinary shares of £0.001 each

 

 

GB00BZ1BLL44

b)

 

Nature of the transaction

 

 

Transfer of ordinary shares to self-invested personal pension (SIPP) via sale and purchase

c)

 

Price(s) and volume(s)

 

 

 

Price(s)

 

Volume(s)

 

Sale of shares from personal holding at 82.5p per share

 

92,750

Purchase by SIPP at 82.5p per share

92,704

 

 

d)

 

Aggregated information

 

 

- Aggregated volume

 

 

- Price

 

 

 

 

 

Weighted average price of 82.5p per share

 

 

 

 

e)

 

Date of the transaction

 

 

4 April 2017

f)

 

Place of the transaction

 

 

London Stock Exchange

 

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

Chris Hancock

 

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Chief Technology Officer

b)

 

Initial notification /Amendment

 

 

Initial

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

Creo Medical Group plc

b)

 

LEI

 

 

N/A

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

 

 

Ordinary shares of £0.001 each

 

 

GB00BZ1BLL44

b)

 

Nature of the transaction

 

 

Transfer of ordinary shares to self-invested personal pension (SIPP) via sale and purchase

c)

 

Price(s) and volume(s)

 

 

 

Price(s)

 

Volume(s)

 

Sale of shares from personal holding at 82.5p per share

 

106,084

Purchase by SIPP at 82.5p per share

106,038

 

 

d)

 

Aggregated information

 

 

- Aggregated volume

 

 

- Price

 

 

 

 

 

Weighted average price of 82.5p per share

 

 

 

 

e)

 

Date of the transaction

 

 

4 April 2017

f)

 

Place of the transaction

 

 

London Stock Exchange

 

 

 

Contacts

Creo Medical:

Cenkos:

FTI Consulting:

Roseanne Varner

+44 (0)129 160 6005 roseanne.varner@creomedical.com

Ivonne Cantu / Camilla Hume (NOMAD)

Michael Johnson / Russell Kerr (Sales)

+44 (0)207 397 8900

Brett Pollard / Mo Noonan

+44 (0)203 727 1000

creo@fticonsulting.com

 

About Creo Medical

Creo Medical, founded in 2003, is a medical device company focused on the development and commercialisation of minimally invasive surgical devices, by bringing advanced energy to endoscopy. The Company's mission is to improve patient outcomes by applying microwave and radiowave energy to surgical endoscopy. Creo has developed CROMA, an electrosurgical platform that combines bipolar radiofrequency for precise localised cutting and microwave for controlled coagulation. This technology provides physicians with flexible, accurate and controlled surgical solutions.

 

The Company's strategy is to bring the CROMA surgical system to market through a suite of medical instruments which the Company has designed, initially for GI therapeutic endoscopy, an area with high unmet needs. The CROMA system will be developed further for bronchoscopy and laparoscopy procedures. The Company believes its technology can impact the landscape of surgery and endoscopy by providing safer, less-invasive and more cost-efficient option of treatment.

 

For more information about Creo Medical please see our website, www.creomedical.com.

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHEAKLLELSXEFF